Boston-based pharma company Ratio Therapeutics has initiated dosing in a phase 1 study evaluating the pharmacokinetics, biodistribution and radiation dosimetry of a novel fibroblast activation protein-alpha (FAP)-targeted radiopharmaceutical, RTX-1363S,...
UCB and Ariceum have announced a strategic research collaboration to identify and develop systemic targeted radiopharmaceuticals for the treatment of solid tumors and immune-related diseases.
Fusion Pharmaceuticals, a clinical-stage oncology company, has announced the opening of its new state-of-the-art radiopharmaceutical manufacturing facility at Ontario-based McMaster University.
The radiopharmaceuticals developer Ariceum Therapeutics has bagged $24.9m (€22.8m) in a Series A extension round. Adding to a $27.4m (€25m) Series A closing last year, the Series A winnings for the German startup now total $52.3m (€47.8m).
